Skip to content

Welcome to Discover Pharma! Today is : November 5, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Grifols

  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Research & Development

    Grifols completes Phase 3 SPARTA study of Prolastin-C in alpha-1 emphysema

    Grifols has completed patient follow-up in its Phase 3 SPARTA [...]

    August 11, 2026
  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas

    Grifols doses first patient in Phase 3 alpha-1 therapy trial

    Grifols has dosed the first participant in a Phase 3 [...]

    July 2, 2026
  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    Grifols launches Fesilty in US for congenital fibrinogen deficiency

    Grifols has launched Fesilty in the USA, making the fibrinogen [...]

    June 16, 2026
  • Advanced Therapies,Pharmaceuticals and therapeutics,Therapeutic Areas

    Grifols fibrinogen concentrate FESILTY approved in the US for acute bleeding in congenital fibrinogen deficiency

    Grifols has received US Food and Drug Administration (FDA) approval [...]

    May 5, 2026
  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    Grifols secures expanded FDA label for Thrombate to include pediatric hereditary antithrombin deficiency

    Grifols has received US FDA approval for an expanded indication [...]

    May 5, 2026
  • Advanced Therapies,Biotech & Pharma Business,Clinical & Regulatory,Therapeutic Areas

    Grifols’ Biotest secures first approval for fibrinogen concentrate in Germany

    Grifols’ Biotest has received its first regulatory approval for a [...]

    May 5, 2026
  • Clinical & Regulatory,Manufacturing & Supply Chain,Pharmaceuticals and therapeutics,Therapeutic Areas

    Grifols’ Biotest launches Yimmugo in United States after FDA approval

    Grifols has expanded its portfolio of plasma-derived therapies in the [...]

    May 5, 2026
  • Advanced Therapies,Biotech & Pharma Business,Drug Delivery & Formulation,Manufacturing & Supply Chain

    XL-protein grants global licence to Grifols for long-acting biologic using PASylation technology

    PASylated candidate to advance into preclinical development under new agreement [...]

    May 5, 2026

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • ETH Zurich develops electronic implant to lower blood glucose
    Categories: Digital & Data, Drug Discovery & Development, Medical devices, Research & Development, Therapeutic Areas
  • Mineralys reports lorundrostat results in hypertension and kidney disease
    Categories: Clinical & Regulatory, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
  • SalubrisBio reports JK06 results across three cancer types
    Categories: Biotech & Pharma Business, Clinical & Regulatory, Drug Discovery & Development, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details.
OK
Go to Top